| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...985245L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0085245 |
| P932 | PMC publication ID | 3922700 |
| P698 | PubMed publication ID | 24533047 |
| P5875 | ResearchGate publication ID | 260213965 |
| P2093 | author name string | Li Zhang | |
| Xuan Wu | |||
| Jing Zhang | |||
| Yan Huang | |||
| Hongyun Zhao | |||
| Ting Zhou | |||
| Ying Tian | |||
| Jianwei Zhang | |||
| Cong Xue | |||
| Tao Qin | |||
| Wenfeng Fang | |||
| Yuanyuan Zhao | |||
| Yue Yan | |||
| Yuxiang Ma | |||
| Peiyu Huang | |||
| Wenhua Liang | |||
| Xue Hou | |||
| Yunpeng Yang | |||
| Zhihuang Hu | |||
| Xiaoxiao Dinglin | |||
| P2860 | cites work | The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer | Q39752575 |
| Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study | Q42633635 | ||
| Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors | Q42781680 | ||
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
| Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. | Q46021186 | ||
| Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial | Q47773490 | ||
| First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung | Q48476437 | ||
| Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy | Q48646738 | ||
| Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) | Q57908992 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Lung cancer | Q29615473 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer | Q33384455 | ||
| Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer | Q33392945 | ||
| A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer | Q33397670 | ||
| No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data | Q33436401 | ||
| Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial | Q33521023 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials | Q34277874 | ||
| Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis | Q34339890 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. | Q34528550 | ||
| Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors | Q36660463 | ||
| Evaluation of networks of randomized trials | Q36966424 | ||
| Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. | Q37080766 | ||
| Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis | Q37334996 | ||
| Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer | Q37344525 | ||
| Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. | Q37659062 | ||
| Treatment of non-small-cell lung cancer with erlotinib or gefitinib | Q37851148 | ||
| LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both | Q38118503 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| patient | Q181600 | ||
| meta-analysis | Q815382 | ||
| erlotinib | Q418369 | ||
| P304 | page(s) | e85245 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations | |
| P478 | volume | 9 |
| Q37705923 | Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts |
| Q92105302 | Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial |
| Q38262804 | Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. |
| Q92354500 | Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer |
| Q39179464 | Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. |
| Q33751194 | Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. |
| Q40829674 | Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. |
| Q90198180 | Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations |
| Q37706099 | Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China |
| Q37572972 | Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. |
| Q28087306 | Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma |
| Q47878958 | Current and emerging EGFR therapies for glioblastoma. |
| Q41065727 | EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer |
| Q26852507 | EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer |
| Q36362830 | Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis |
| Q90573313 | Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis |
| Q52658297 | Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. |
| Q46008308 | Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. |
| Q91741741 | Emerging non-invasive detection methodologies for lung cancer |
| Q34814528 | Fatal interstitial lung disease associated with icotinib |
| Q47763039 | First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study |
| Q26471909 | First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer |
| Q64228070 | First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis |
| Q38338492 | Gefitinib: a review of its use in adults with advanced non-small cell lung cancer |
| Q38776722 | High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival |
| Q64112610 | IVS2vec: A tool of Inverse Virtual Screening based on word2vec and deep learning techniques |
| Q38352862 | Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer |
| Q47150078 | Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro. |
| Q30658102 | Identification of putative drug targets for human sperm-egg interaction defect using protein network approach |
| Q88648647 | Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1 |
| Q60921926 | Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression |
| Q36452604 | Is Local Infiltration Analgesia Superior to Peripheral Nerve Blockade for Pain Management After THA: A Network Meta-analysis |
| Q96123809 | Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs |
| Q35807946 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib |
| Q39954639 | Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis |
| Q36750945 | Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. |
| Q41487456 | Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors |
| Q92581906 | Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines |
| Q35810510 | Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy |
| Q64112059 | Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis |
| Q36474226 | Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma |
| Q38390200 | Targeted therapy for non-small cell lung cancer: current standards and the promise of the future |
| Q46436702 | Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma |
| Q91839462 | The anti-metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2-dependent manner |
| Q39458466 | The anticipated next season of EGFR inhibitors |
| Q51733149 | Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. |
| Q26991969 | Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib |
| Q33662730 | Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. |
| Q38222703 | Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? |
| Q90376650 | lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2 |
Search more.